Navigate by Cancer Type
For each cancer, compare treatment options, best destinations, budget bands, and urgency levels.
Blood Cancers
Leukemia • Lymphoma • Myeloma — the highest success rates with cellular therapy
Breast Cancer
HER2+ • Triple-Negative • ER+ — advanced targeted therapy pathways
Lung Cancer
NSCLC • SCLC — targeted therapies, immunotherapy, and clinical trials
Liver Cancer
HCC • Cholangiocarcinoma — cellular therapy and interventional approaches
Brain Tumors
Glioblastoma • Astrocytoma — 14 active trials in China alone
Pancreatic Cancer
Pancreatic ductal adenocarcinoma — emerging cellular therapy options
Navigate by Treatment Goal
Already know what treatment you need? Find the best destination for your specific goal.
Best Path for CAR-T
Access the world's largest CAR-T ecosystem. 700+ active trials in China plus FDA-approved products in USA and EMA-approved in Germany.
Best Path for Proton Therapy
Precision radiation with minimal collateral damage. Ideal for brain, pediatric, and anatomically complex tumors.
Most Cost-Effective Path
Access advanced therapies at 70-85% less than US/EU prices. India and China lead in cost-effective cellular therapy.
Fastest Access Path
For patients who need treatment within weeks. China's streamlined trial activation enables 3-4 week referral-to-treatment.
Best Path for Second Opinion
Get a free expert second opinion from board-certified oncologists within 48 hours. No obligation.
Best Path for Trial Access
Access clinical trials not available in your home country. 700+ CAR-T trials in China, plus trials across 7 other countries.
Quick Country Comparison
At-a-glance comparison of cost, speed, and specialization across our partner countries.
China
South Korea
Singapore
India
Turkey
Germany
Full Decision Matrix
Scan across cancer types, treatment options, countries, budgets, and timelines.
| Cancer Type | Treatment | Best Country | Budget | Time | Language | Best For |
|---|---|---|---|---|---|---|
| Blood Cancers | CAR-T | 🇨🇳 China | $30K-$80K | 2-4 w | CN/EN | Relapsed/Refractory |
| Blood Cancers | CAR-T | 🇺🇸 USA | $373K-$475K | 8-12 w | EN | FDA-Approved |
| Blood Cancers | NK Cells | 🇨🇳 China | $25K-$60K | 3-5 w | CN/EN | Lower toxicity |
| Breast Cancer | Proton | 🇰🇷 Korea | $80K-$150K | 4-6 w | KO/EN | Left-sided tumors |
| Breast Cancer | Targeted | 🇩🇪 Germany | $60K-$120K | 6-8 w | DE/EN | HER2+ precision |
| Lung Cancer | TIL | 🇨🇳 China | $40K-$80K | 3-5 w | CN/EN | Solid tumors |
| Brain Tumors | CAR-T | 🇨🇳 China | $64K-$99K | 3-4 w | CN/EN | 14 active trials |
| Brain Tumors | DCVax | 🇨🇳 China | $55K-$65K | 4-6 w | CN/EN | Newly diagnosed |
| Liver Cancer | Gamma Delta | 🇨🇳 China | $30K-$60K | 2-4 w | CN/EN | HCC without HLA |
| Pancreatic | Trials | 🇩🇪 Germany | $120K-$250K | 8-10 w | DE/EN | Research-grade |
| Pediatric | Proton | 🇰🇷 Korea | $60K-$120K | 4-6 w | KO/EN | Reduced radiation |
| All Cancers | Second Opinion | 🌍 All | FREE | 48 h | 7 languages | Expert review |
Disclaimer: This is a decision-support tool, not medical advice. All treatment decisions are made by licensed physicians at partner institutions. Read our full Legal Framework →
Frequently Asked Questions
Common questions about navigating treatment destinations.
The best country depends on your cancer type, stage, budget, treatment goals, and urgency. Use our Destination Navigator to compare: China leads in CAR-T trials (700+), South Korea and Germany excel in proton therapy, India and Turkey offer cost-effective advanced care, and the USA provides FDA-approved therapies. Submit your case for a personalized pathway recommendation.
CAR-T therapy costs vary dramatically: China $30K-$80K, India $40K-$90K, Turkey $80K-$150K, Germany $180K-$350K, USA $373K-$475K. Total cost of care adds 20-40% for travel, accommodation, and follow-up. Visit our Cost Transparency page for detailed breakdowns.
China offers the fastest access: 2-4 weeks from referral to treatment for clinical trials. India and Turkey: 4-8 weeks. USA and Europe: 8-12 weeks for standard care. Expedited pathways available for urgent cases with performance status ECOG 0-2.
Yes. Most partner institutions offer telemedicine pre-consultation. You can submit your medical records through our secure portal and receive a preliminary assessment within 48 hours. This helps determine eligibility before travel arrangements.
Submit through our secure online form (HIPAA-aligned encryption). Required documents: pathology report, recent imaging (MRI/CT/PET in DICOM format), treatment history, and current medication list. Our team pre-screens within 48 hours and recommends matching pathways.
No. All coordination services are completely free for patients. Our platform is sustained through institutional partnerships with hospitals. Patients never pay us any fees, commissions, or hidden charges. If anyone claims to charge on our behalf, report to info@cancercaree.com.
Start Your Personalized Pathway
Submit your case for a free, no-obligation assessment. Our oncology team will match your specific situation with the best destination and treatment options within 48 hours.
Submit Your Case NowFree • Confidential • 48-Hour Response • No Obligation